Dermato‐neuro syndrome after COVID‐19 infection in a patient with scleromyxoedema: Previously successful treatment with intravenous immunoglobulins

Abstract Scleromyxedema (SMX) is a rare disease of unknown cause. It is a chronic, progressive, metabolic disorder characterized by a generalized papular and scleroderma‐like rash, as well as a subtype of lichen myxedematosus. Dermato‐neuro syndrome (DNS) is a rare neurological complication of SMX. It has flu‐like prodromal symptoms; consists of a triad of fever, coma, and seizures; and can be life‐threatening. We describe a patient with SMX complicated by DNS after infection with COVID‐19. Her symptoms resolved after treatment with acyclovir and low‐dose glucocorticoids, suggesting that DNS seizures may have a viral cause. Her skin lesions also improved after seven courses of intravenous immunoglobulin treatment, confirming that intravenous immunoglobulin is effective in these cases.